Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes

被引:28
|
作者
Boehm, Anna-Katharina [1 ]
Schneider, Udo [2 ]
Aberle, Jens [3 ]
Stargardt, Tom [1 ]
机构
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, Hamburg, Germany
[2] Techniker Krankenkasse, Hamburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Univ Obes Ctr Hamburg, Dept Endocrinol & Diabetol, Hamburg, Germany
来源
PLOS ONE | 2021年 / 16卷 / 05期
关键词
DUAL THERAPY; MONOTHERAPY; NONADHERENCE; PERSISTENCE; COPAYMENTS; IMPACT;
D O I
10.1371/journal.pone.0250993
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Suboptimal patient adherence to pharmacological therapy of type 2 diabetes may be due in part to pill burden. One way to reduce pill burden in patients who need multiple medications is to use fixed-dose combinations. Our study aimed to compare the effects of fixed-dose combination versus loose-dose combination therapy on medication adherence and persistence, health care utilization, therapeutic safety, morbidities, and treatment modification in patients with type 2 diabetes over three years. Methods Using administrative data, we conducted a retrospective controlled cohort study comparing type 2 diabetes patients who switched from monotherapy to either a fixed-dose combination or a loose-dose combination. Adherence was assessed as the primary endpoint and calculated as the proportion of days covered with medication. After using entropy balancing to eliminate differences in observable baseline characteristics between the two groups, we applied difference-in-difference estimators for each outcome to account for time-invariant unobservable heterogeneity. Results Of the 990 type 2 diabetes patients included in our analysis, 756 were taking a fixed-dose combination and 234 were taking a loose-dose combination. We observed a statistically significantly higher change in adherence (year one: 0.22, p<0.001, year two: 0.25, p<0.001, and year three: 0.29, p<0.001) as well as higher persistence and a smaller change in the number of drug prescriptions in each of the three years in the fixed-dose combination group compared to the loose-dose combination group. The differences were most pronounced in patients who were poorly adherent, had a high pill burden, or did not have a severe concomitant disease. Conclusion Our results indicate that taking a fixed-dose combination can lead to a significant improvement in adherence to pharmacological therapy of type 2 diabetes compared to a loose-dose combination. In particular, these findings suggest that reducing pill burden may improve disease management among patients with more complex medication demand and patients who have demonstrated poor medication adherence.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes
    Joshi, Shashank R.
    Ramachandran, Ambady
    Chadha, Manoj
    Chatterjee, Sudip
    Rathod, Rahul
    Kalra, Sanjay
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1611 - 1620
  • [32] Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
    Jaime A. Davidson
    Lance Sloan
    [J]. Advances in Therapy, 2017, 34 : 41 - 59
  • [33] Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination
    Fleming, Joshua W.
    Fleming, Laurie W.
    Davis, Courtney S.
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 287 - 294
  • [34] Comparison of medication adherence between fixed-dose combination of angiotensin receptor blockers and statin and free-combination therapy
    Choi, J. H.
    Choi, J. M.
    Jang, Y. J.
    Kang, M.
    Lee, S. H.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 2779 - 2779
  • [35] Retrospective comparison of compliance to fixed-dose combination versus single agent combination therapy for the treatment of diabetes
    Patel, B., V
    Leslie, R. S.
    Aranda, G. A.
    McCoy, M.
    Baran, R. W.
    Xu, Y.
    Bron, M.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A275 - A275
  • [36] Fixed-dose Combination Therapy in Hypertension: Focus on Fixed-dose Combination of Amlodipine and Valsartan (Exforge (R))
    Aslam, Shakil
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1521 - 1529
  • [37] Fixed-dose combination antihypertensives and risk of medication errors
    Moriarty, Frank
    Bennett, Kathleen
    Fahey, Tom
    [J]. HEART, 2019, 105 (03) : 204 - 209
  • [38] Improved adherence with rosiglitazone/netformin fixed-dose combination therapy: A retrospective analysis
    Vanderpoel, DR
    Hussein, MA
    Watson-Heidari, T
    Dirani, RG
    Perry, A
    [J]. DIABETES, 2004, 53 : A481 - A482
  • [39] Fixed-Dose Combination Therapy in Hypertension Cons
    Angeli, Fabio
    Reboldi, Gianpaolo
    Mazzotta, Giovanni
    Garofoli, Marta
    Ramundo, Elisa
    Poltronieri, Cristina
    Verdecchia, Paolo
    [J]. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2012, 19 (02) : 51 - 54
  • [40] History of fixed-dose combination therapy for hypertension
    Wofford, JL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (09) : 1044 - 1044